Fred Hutchinson Cancer Research Center Lung SPORE

Fred Hutchinson 癌症研究中心肺孢子

基本信息

批准号：
10436169
负责人：
A McGarry Houghton
金额：
$ 244.71万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10436169
关键词：
Address Antigens Atypical lymphocyte Autologous Benign Bioinformatics Biological Markers Biometry CREBBP gene Cancer Etiology Cancer Patient Cell Lineage Cessation of life Chromatin Clinical Colorado Data Set Development Diagnosis Diagnostic Evaluation Fred Hutchinson Cancer Research Center Genes Genetic Determinism Genotype Goals Gold Histopathology Hybrids Image Analysis Immune checkpoint inhibitor Immune response Immunotherapy Infrastructure KDM1A gene Lung Lung CAT Scan Lung nodule Lymphocyte Malignant - descriptor Malignant neoplasm of lung Medical Methodology Modeling Mutation Neoplasm Circulating Cells Nivolumab Non-Small-Cell Lung Carcinoma Oncogenes Operative Surgical Procedures Patient-Focused Outcomes Patients Performance Phase I Clinical Trials Phase II Clinical Trials Plasma Prognosis Proteins Research Research Design Research Personnel Research Project Grants Resources Specimen Survival Rate T cell therapy T-Lymphocyte Testing Therapeutic Time Translational Research Vaccines X-Ray Computed Tomography antagonist antigen test base bench to bedside cancer cell cancer immunotherapy career checkpoint therapy clinical care cohort early screening effective therapy human tissue imaging biomarker improved industry partner inhibitor innovation lung cancer screening lung small cell carcinoma mouse model neoantigens neutrophil novel patient derived xenograft model patient response programs radiological imaging radiomics receptor response risk prediction model risk stratification screening success therapeutic target translational cancer research treatment response tumor tumor microenvironment

项目摘要

Project Summary/Abstract – Overall The Fred Hutch Lung SPORE consists of four innovative projects, three supportive cores, and the required Developmental Research Program and Career Enhancement Program. We have leveraged the strengths of the investigators and our Center to tackle three critical barriers precluding meaningful improvements in lung cancer survival rates: facilitation of pulmonary nodule evaluation for lung cancer early detection and screening, lack of effective therapies for small cell lung cancer (SCLC), and the sub-optimal response rates of non-small cell lung cancer (NSCLC) patients to novel immune-based therapies. To overcome these barriers, we propose the following four projects: 1) Targeting the Neutrophil Lineage to Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC, 2) Targeting Neoantigens for Lung Cancer Immunotherapy, 3) Identifying Determinants of Sensitivity to LSD1 Inhibition in SCLC, and 4) Risk Stratification for Pulmonary Nodules Detected by CT Imaging Using Plasma and Imaging Biomarkers. These projects will be supported by an Administrative Core, a Biostatistics and Bioinformatics Core (BBC), and a Histopathology and Biospecimen Core (HBC).

项目摘要/摘要 - 总体弗雷德·哈奇（Fred Hutch）肺孢子由四个创新项目，三个支持核心组成，所需的发展研究计划和职业增强计划。我们利用了调查人员和我们的中心解决三个关键障碍，排除肺部有意义的改善癌症存活率：肺癌评估肺癌早期检测的促进和筛查，缺乏针对小细胞肺癌（SCLC）的有效疗法，以及最佳反应率非小细胞肺癌（NSCLC）患者进行新型免疫疗法。为了克服这些障碍，我们提出以下四个项目：1）针对中性粒细胞谱系以增强免疫检查点 NSCLC中的抑制剂功效，2）针对新抗原的肺癌免疫疗法，3）确定 SCLC中对LSD1抑制的敏感性的决定因素，4）肺结节的风险分层使用血浆和成像生物标记物检测到CT成像。这些项目将得到行政核心，生物统计学和生物信息学核心（BBC），以及组织病理学和生物测试核心（HBC）。